The Potential for DPPIV/CD26 usage as a surrogate marker for Antiretroviral Therapy Efficacy in HIV Infected populations
Abstract
Background: Human Immunodeficiency Virus (HIV) viral load and CD4+ cell counts are the most commonly used markers for monitoring efficacy of anti-retroviral therapy (ART) in HIV infected individuals. The high cost of viral load monitoring limits its usage in resource limited countries, often leaving the use of CD4+ T cell counts as the only alternative. Though cheaper and more readily available, CD4+ cell counts as a measure of detecting treatment failure, is an unreliable predictor of disease progression. Hence, there is a need for more sensitive alternative, but less costly techniques for detecting treatment failure which can be used in resource limited settings.
Objective: To evaluate the feasibility of using plasma CD26/Dipeptidyl peptidase IV (DPPIV) as a novel marker for clinical evaluation of treatment efficacy in HIV infected children.
Method: Blood samples collected from HIV+ children (n=76) before and after initiation on ART, were assessed for HIV RNA (viral load), CD4+ T-cell count and DPPIV/CD26 levels. Viral load levels were analyzed using Roche Amplicor HIV-1 Monitor Test kit; CD4+ T-Cell Counts were analyzed using BD FACS Calibur flow cytometer while DPPIV/CD 26 levels were analyzed using Human DPPIV/CD26 Quantikine ELISA kit (R&D Systems, Minneapolis MN).
Results: The plasma DPPIV/CD26 levels increased significantly in children after ART initiation (p = 0.017), while the viral load levels declined after ART initiation with subsequent CD4+ cell counts increase. The DPPIV/CD 26 increase positively correlated with viral load decrease while negatively correlating to the CD4+ cell count increase.
Conclusion: These findings demonstrate an inverse relationship between DPPIV/CD26 levels and HIV viral load and the direct proportionality of CD4+ Cell counts and DPPIV/CD26 levels, suggesting potential for use of DPPIV/CD26 as a surrogate marker for evaluating HIV disease progression in children receiving anti-retroviral therapy.
Key words: CD26/Dipeptidyl peptidase IV (DPPIV), ELISA, Surrogate marker, Viral Load, CD4 Count, antiretroviral.
References
Adler D, Kürktschiev D, Subat S, Lehmann HU, Schentke KU (1993). Dipeptidyl peptidase IV of peripheral blood lymphocytes in patients with primary biliary cirrhosis. Z Gastroenterol. 31:135-9.
Aso Y, Ozeki N, Terasawa T, Naruse R, Hara K, Suetsugu M, Takebayashi K, Shibazaki M, Haruki K, Morita K, Inukai T (2012).Serum level of soluble CD26/dipeptidyl peptidase-4 (DPP-4) predicts the response to sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes controlled inadequately by metformin and/or sulfonylurea. Transl. Res. 159:25-31
Barré-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J and Montagnier L (1983). Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science. 220:868-871.
Boonacker E, Cornelis J, Van Noordern F (2003). The multifunctional or moonlighting protein DPPIV/CD26. Eur. J. Cell Biol. 82:53-73.
Brenner BG, Roger M, Routy JP, Misi D, Ntemgwa M, Matte C. and Wainberg MA (2007). High rates of forward transmission events after acute/early HIV-1 infection. J. Infect. Dis. 195: 951-959.
Bunupuradah T, Wannachai S, Chuamchaitrakool A, Intasan J, Nuchapong T, Neiss W (2006).Use of taste-masking product, FLAVORx, to assist Thai children to ingest generic antiretrovirals. AIDS Res. Ther. 3:30.
Cairns G (2009). Cheap viral load test is as reliable as standard: Botswana places large order. Available at: http://www.aidsmap.com/Cheap-viral-load-test-is-as-reliable-as-standard-Botswana-places-large-order/page/1435855/ (Accessed: December 2016)
Cordero OJ, Salgado FJ, Nogueira M (2009). On the origin of serum CD26 and its altered concentration in cancer patients. Cancer Immunol. Immunother. 58:1723–1747.
de la Haba-Rodríguez J, Macho A, Calzado MA, Blázquez MV, Gómez MA, Muñoz EE, Aranda E (2002).Soluble dipeptidyl peptidase IV (CD-26) in serum of patients with colorectal carcinoma. Neoplasma. 49:307-11.
Dong RP, Morimoto C (1996).Role of CD26 for CD4 memory T cell function and activation. Hum Cell. 9:153-162.
Fukushima K, Shibata M, Mizuhara K, Aoyama H, Uchisako R, Kobuchi S (2009).Effect of serum lipids on the pharmacokinetics of atazanavir in hyperlipidemic rats. Biomed. Pharmacother. 63:635–42.
Gallo R C (2006).A reflection on HIV/AIDS research after 25 years. Retrovirology, 3: 72.
Gazzola L, Tincati C, Bellistré GM, Monforte, ADA and Marchetti G (2009).The absence of CD4+ T cell count recovery despite receipt of virologically suppressive highly active antiretroviral therapy: clinical risk, immunological gaps, and therapeutic options. Clin. Infect. Dis. 48:328-337.
Gottlieb MS, Schroff R, Schanker HM, Weisman JD, Fan PT, Wolf RA and Saxon A (1981). Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. New Eng. J. Med. 305: 1425-1431.
Havre PA, Abe M, Urasaki Y, Ohnuma K, Morimoto C, Dang NH (2008). The role of CD26/dipeptidyl peptidase IV in cancer. Front. Biosci. 13:1634–1645.
Heald AE, Pieper CF, Schiffman SS (1998). Taste and smell complaints in HIV-infected patients. AIDS, 12:1667-74.
Hogg RS, Yip B, Chan KJ, Wood E, Craib KJ, O'Shaughnessy MV and Montaner JS (2001).Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA, 286: 2568-2577.
Iwaki-Egawa S, Watanabe Y, Kikuya Y, Fujimoto Y. (1998) .Dipeptidyl peptidase IV from human serum: purification, characterization, and N-terminal amino acid sequence. J Biochem. 124: 428–433.
Jain V, Hartogensis W, Bacchetti P (2013). Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size. J. Infect. Dis. 208:1202-1211.
Janossy G, Mandy F, and O’Gorman MRG (2008). Diagnostics in the shadow of HIV epidemics. Cytometry B: Clin. Cytom. 74:1–3.
Katzenstein D, Laga M and Moatti, JP (2003).The evaluation of the HIV/AIDS drug access initiatives in Cote d'Ivoire, Senegal and Uganda: how access to antiretroviral treatment can become feasible in Africa. AIDS, 17:1-4.
Murphy EL, Collier AC, Kalish LA, Assmann SF, Para MF, Flanigan TP and Nemo GJ (2001). Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann. Intern. Med. 135: 17-26.
Natella Rakhmanina and Ryan Phelps (2012). Pharmacotherapy of Pediatric HIV Infection. Pediatr. Clin. North Am. 59: 1093–1115.
Neely MN, Rakhmanina NY (2011). Pharmacokinetic optimization of antiretroviral therapy in children and adolescents. Clin. Pharmacokinet. 50:143–89.
Nkengasong JN, Birx D, Sankalé JL (2009). Challenges in Developing Laboratory Capacity and Infrastructure to Support HIV/AIDS Care Programs. In: From the Ground Up: Building Comprehensive HIV/AIDS Care Programs in Resource-Limited Settings. Marlink RG, Teitelman ST, Eds. Washington, DC: Elizabeth Glaser Pediatric AIDS Foundation.
Ohnuma K, Takahashi N, Yamochi T (2008). Role of CD26/dipeptidyl peptidase IV in human T cell activation and function. Front. Biosci. 13:2299-310.
Ohtsuki T, Tsuda H, Morimoto C (2000). Good or Evil: CD26 and HIV Infection. J. Dermatol. Sci. 22:152-60.
Paintsil E (2011). Monitoring antiretroviral therapy in HIV-infected children in resource-limited countries: a tale of two epidemics. AIDS research and treatment. AIDS Res. Treat. doi: 10.1155/2011/280901
Reeves JD, Piefer AJ (2006). Emerging drug targets for antiretroviral therapy. Drugs. 65: 1747-1766
Schüpbach J, Haller O, Vogt M, Lüthy R, Joller H, Oelz O and Gallo RC (1985). Antibodies to HTLV-III in Swiss patients with AIDS and pre-AIDS and in groups at risk for AIDS. New Eng. J. Med. 312: 265-270.
Songok EM, Osero B, Mckinnon L, Rono MK., Apidi W, Matey EJ and Mpoke S (2010).CD26/dipeptidyl peptidase IV (DPPIV/CD26) is highly expressed in peripheral blood of HIV-1 exposed uninfected Female sex workers. Virol. J. 7:1-7.
UNAIDS report on HIV/AIDS (2015). AIDS by the numbers.
UNAIDS Report on the Global AIDS Epidemic (2013). Joint United Nations Programme on HIV/AIDS.
Vernazza PL, Troiani L, Flepp MJ (2000). Potent antiretroviral treatment of HIV-infection results in suppression of the seminal shedding of HIV. The Swiss HIV Cohort Study. AIDS, 14:117-121.
Wainberg MA and Jeang KT (2008). 25 years of HIV-1 research–progress and perspectives. BMC Med. 6: 31.
Wang S, Xu F and Demirci U (2010).Advances in developing HIV-1 viral load assays for resource-limited settings. Biotechnol. Adv. 28: 770-781.
World Health Organization (2015)-HIV/AIDS guidelines.
Wrenger S, Hoffmann T, Faust J, Mrestani-Klaus C, Brandt W, Neubert K and Reinhold D (1997).The N-terminal structure of HIV-1 Tat is required for suppression of CD26-dependent T cell growth. J. Biol. Chem. 272: 30283-30288.
Full Text: PDF
Refbacks
- There are currently no refbacks.